Paclitaxel Injection, Powder, Lyophilized, For Suspension
Product Images NDC 67457-937

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Paclitaxel (NDC 67457-937). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Institutional Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Paclitaxel Protein-bound Injection 100 mg Carton (Image 01)

Paclitaxel Protein-bound Injection 100 mg Carton (Image 01)
This text appears to be a detailed description of a pharmaceutical product labeled as a cytotoxic agent called Paclitaxel Protein-Bound Particles for Injectable Suspension. It mentions instructions for reconstitution with 9% Protein-Bound Chloride Injection, dosage information, storage requirements, and usage precautions, emphasizing that it is for Intravenous Use Only. The text also highlights the functional differences of this albumin-bound form of Paclitaxel from other products and warns against substitution. It is manufactured in India under the Mylan brand and comes in a single-dose vial. The importance of proper storage, infusion rate verification, and discarding any unused portion is stressed.*
FDA Label Image

Figure 1, Preparation Instructions (Image 02)

Figure 1, Preparation Instructions (Image 02)
FDA Label Image

Paclitaxel Structural Formula (Image 03)

Paclitaxel Structural Formula (Image 03)
FDA Label Image

Figure 1: Kaplan-meier Curve Of Overall Survival (intent-to-treat Population) (Image 04)

Figure 1: Kaplan-meier Curve Of Overall Survival (intent-to-treat Population) (Image 04)
This is a dataset depicting the proportion of survival over time for injectable suspensions of paclitaxel protein-bound particles (albumin-bound) used in cancer treatment. The data includes the number of patients at risk at different time points represented in months. Key information includes the number of patients at risk for each treatment group (PAC/GEM and GEN), as well as survival proportions over time.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.